2017 News

10 October 2017

Gendius announces funding from Catapult Ventures to launch innovative digital health platform for patients living with diabetes

Alderley Park, UK – 5th October 2017. Gendius, a digital health start-up developing a solution for patients living with diabetes to better manage their condition, today announced the completion of a Series A funding to launch Intellin® - an App based platform for people living with diabetes. The funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.

Diabetes is a global epidemic. The economic cost of treating diabetes in 2014 is estimated at over $600bn and the latest WHO report predicts there will be 592m sufferers around the world by 2035. Healthcare systems are desperate for novel solutions to engage and empower people to manage their diabetes more effectively and mobile technologies are spearheading many of these initiatives, and are predicted to be worth US$102.43bn by 2022, largely driven by Applications.

Gendius was founded by Chris Genders and Rory Cameron with a view to making living with diabetes easier. The company has developed Intellin® - an App platform that uses an individual’s clinical history to predict those areas most likely of developing complications from their diabetes i.e. their individual high-risk areas. The platform then focusses the individual on clinically validated tasks and measures to slow their progression in these areas. The Intellin® platform is currently undergoing clinical trials and has won significant grant funding from both Innovate UK and the SBRI.

In addition to the investment, Chris Spencer, a Digital Health Advisor with Catapult Ventures, will join the board of Gendius as non-executive Chairman in early 2018. Until April 2017 Chris was CEO of EMIS Group Plc where he had held senior roles since 1999.

Chris Genders, CEO Gendius, said “I’m extremely pleased to welcome the GM&C Life Sciences Fund as an investor in Gendius and welcome Chris as Chair elect. Chris’s wide-ranging experience in the leadership and management of healthcare technology businesses will be extremely valuable to Gendius as we seek to further enhance and commercialise our digital applications for diabetes and grow Gendius as a leader in this area.”

Dr Vijay Barathan, Life Science Partner with Catapult Ventures, said “We are excited by this opportunity and fully support the approach Gendius is taking to develop a scalable and sustainable digital health business.”

Chris Spencer, Digital Health Advisor with Catapult Ventures, said “I am looking forward to working with Chris, Rory, and the team to fulfil the potential of their Application to improve clinical outcomes in this area of high patient need and payer/provider cost.”

Photo L-R:  Rory Cameron – COO, Gendius; Chris Genders – CEO, Gendius; Vijay Barathan – Life Science Partner, Catapult Ventures; Chris Spencer – Digital Health Advisor, Catapult Ventures

From our portfolio

Pencil Biosciences


viewview our portfolio

Our Team

Dr David Whitcombe

view complete team

Contact us

Tel: 01625 344300